StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.41−0.01 (-2.13%)

Close on Nov 16, 2026Market cap $7.97MP/E –Yield –

Ensysce Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Ensysce Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.39M, up 33.2% year over year. For fiscal 2025 it was $10.38M, up 43.7% from the year before. The highest annual figure on record is $19.84M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.38M+43.7%
FY2024Dec 31, 2024$7.22M-4.9%
FY2023Dec 31, 2023$7.59M-61.7%
FY2022Dec 31, 2022$19.84M+322.9%
FY2021Dec 31, 2021$4.69M+6.8%
FY2020Dec 31, 2020$4.39M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.47M+28.5%
Q1 FY2026Mar 31, 2026$3.35M+77.5%
Q4 FY2025Dec 31, 2025$3.61M-5.0%
Q3 FY2025Sep 30, 2025$2.95M+74.8%
Q2 FY2025Jun 30, 2025$1.92M+103.1%
Q1 FY2025Mar 31, 2025$1.89M+142.1%
Q4 FY2024Dec 31, 2024$3.80M+70.3%
Q3 FY2024Sep 30, 2024$1.69M-11.7%
Q2 FY2024Jun 30, 2024$947.23K-42.4%
Q1 FY2024Mar 31, 2024$778.90K-56.6%
Q4 FY2023Dec 31, 2023$2.23M-65.3%
Q3 FY2023Sep 30, 2023$1.91M-59.7%
Q2 FY2023Jun 30, 2023$1.64M-69.1%
Q1 FY2023Mar 31, 2023$1.80M-42.8%
Q4 FY2022Dec 31, 2022$6.44M+194.4%
Q3 FY2022Sep 30, 2022$4.76M+177.4%
Q2 FY2022Jun 30, 2022$5.31M+1046.6%
Q1 FY2022Mar 31, 2022$3.14M+1004.2%
Q4 FY2021Dec 31, 2021$2.19M+74.6%
Q3 FY2021Sep 30, 2021$1.71M+92.0%
Q2 FY2021Jun 30, 2021$463.22K-67.0%
Q1 FY2021Mar 31, 2021$284.38K–
Q4 FY2020Dec 31, 2020$1.25M–
Q3 FY2020Sep 30, 2020$892.99K–
Q2 FY2020Jun 30, 2020$1.40M–

More Ensysce Biosciences figures

See a number that looks wrong?